Viridian Therapeutics, Inc. (0K1R.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 07:12PM BST. Market open.
| Previous close | 14.68 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 682 |
| Market cap | 3.12M |
| Beta (5Y monthly) | 1.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.14 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Viridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Viridian Therapeutics ( NASDAQ:VRDN ) First Quarter 2024 Results Key Financial Results Net loss: US$48.5m (loss...
- GuruFocus.com
Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Discover key insights from VRDN's Q1 2024 earnings, including trial successes, financial stability, and future regulatory plans.
GuruFocus.comViridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements
How VRDN's Financial Performance Measures Up Against Market Expectations
© 2024 Yahoo. All rights reserved.